Combination of Tramiprosate, Curcumin, and SP600125 Reduces the Neuropathological Phenotype in Familial Alzheimer Disease PSEN1 I416T Cholinergic-like Neurons
Open Access
- 30 April 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4925
Abstract
Familial Alzheimer’s disease (FAD) is a complex and multifactorial neurodegenerative disorder for which no curative therapies are yet available. Indeed, no single medication or intervention has proven fully effective thus far. Therefore, the combination of multitarget agents has been appealing as a potential therapeutic approach against FAD. Here, we investigated the potential of combining tramiprosate (TM), curcumin (CU), and the JNK inhibitor SP600125 (SP) as a treatment for FAD. The study analyzed the individual and combined effects of these two natural agents and this pharmacological inhibitor on the accumulation of intracellular amyloid beta iAβ; hyperphosphorylated protein TAU at Ser202/Thr205; mitochondrial membrane potential (ΔΨm); generation of reactive oxygen species (ROS); oxidized protein DJ-1; proapoptosis proteins p-c-JUN at Ser63/Ser73, TP53, and cleaved caspase 3 (CC3); and deficiency in acetylcholine (ACh)-induced transient Ca2+ influx response in cholinergic-like neurons (ChLNs) bearing the mutation I416T in presenilin 1 (PSEN1 I416T). We found that single doses of TM (50 μM), CU (10 μM), or SP (1 μM) were efficient at reducing some, but not all, pathological markers in PSEN 1 I416T ChLNs, whereas a combination of TM, CU, and SP at a high (50, 10, 1 μM) concentration was efficient in diminishing the iAβ, p-TAU Ser202/Thr205, DJ-1Cys106-SO3, and CC3 markers by −50%, −75%, −86%, and −100%, respectively, in PSEN1 I417T ChLNs. Although combinations at middle (10, 2, 0.2) and low (5, 1, 0.1) concentrations significantly diminished p-TAU Ser202/Thr205, DJ-1Cys106-SO3, and CC3 by −69% and −38%, −100% and −62%, −100% and −62%, respectively, these combinations did not alter the iAβ compared to untreated mutant ChLNs. Moreover, a combination of reagents at H concentration was able to restore the dysfunctional ACh-induced Ca2+ influx response in PSEN 1 I416T. Our data suggest that the use of multitarget agents in combination with anti-amyloid (TM, CU), antioxidant (e.g., CU), and antiapoptotic (TM, CU, SP) actions might be beneficial for reducing iAβ-induced ChLN damage in FAD.Keywords
Funding Information
- Minciencias (1115-844-67062, 10.2.593.2024)
- Neuroscience Research Group (1115-844-67062, 10.2.593.2024)
This publication has 110 references indexed in Scilit:
- Donepezil-based combination therapy for Alzheimer’s disease and related neuropathiesComparative Clinical Pathology, 2023
- Alzheimer's disease drug development pipeline: 2023Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2023
- NIH Pilots Telehealth Program for COVID-19JAMA, 2023
- Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's DiseaseNeurotherapeutics, 2022
- Latent Tri-lineage Potential of Human Menstrual Blood–Derived Mesenchymal Stromal Cells Revealed by Specific In Vitro Culture ConditionsMolecular Neurobiology, 2021
- Expression and secretion of apoE isoforms in astrocytes and microglia during inflammationGlia, 2021
- Increased bioavailability of curcumin using a novel dispersion technology system (LipiSperse®)European Journal of Nutrition, 2018
- Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: ReviewPhytotherapy Research, 2018
- Amyloid-β and TauJAMA Neurology, 2014
- Clinical Features of Early-Onset Alzheimer Disease in a Large Kindred With an E280A Presenilin-1 MutationJAMA, 1997